AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

Paired with AMPEL’s pipeline of tools to analyze very large and complex clinical datasets (“Big Data”), FibroGENE® is a significant step towards implementing a routine test for monitoring fibromyalgia and providing decision support for treatment based on a patient’s gene expression. This will transform the way doctors treat fibromyalgia by using the information gathered by the lab test and analyzed by bioinformatics to characterize the precise molecular abnormalities and treat symptoms, reduce pain and increase the quality of life of millions of Americans. 

read more
Experimental Blood Test Could Improve Fibromyalgia Treatment

Experimental Blood Test Could Improve Fibromyalgia Treatment

A small pilot study suggests an experimental blood test for fibromyalgia – called FibroGENE — could be used to determine which drug works best for each patient. Researchers at AMPEL BioSolutions and Duke University Medical Center found genetic biomarkers in the blood cells of 18 lupus patients with fibromyalgia-like symptoms.

read more
Local company unveils blood test to find treatments for chronic pain

Local company unveils blood test to find treatments for chronic pain

A medical discovery has been made in Charlottesville that may help people who experience chronic pain, fatigue and brain fog. “This is a big problem. This is a clinical problem that is not addressed. And it’s a problem that tends to discount patients,” said CEO and Chief Medical Officer Peter Lipsky.

read more

Pin It on Pinterest